DarioHealth (NSDQ:DRIO) said today that it inked a deal with an unnamed pharmaceutical company to combine its blood glucose monitoring tech into the company’s clinical trial.
The Israel-based device-maker reported that this pharmaceutical company is conducting a trial of its diabetes drug that will eventually be included in a regulatory package for FDA approval.
DarioHealth has been tasked with tracking the blood glucose levels of the trial’s participants.
“We are thrilled to have been chosen for this important clinical study. Our Dario all-in-one platform was selected because of its ability to help patients in all aspects of managing diabetes with stronger user engagement, and real-time access to results. This move into clinical studies and clinician practices shows the adoption of our products and solutions going beyond the scope of just the consumer,” chairman & CEO Erez Raphael said in prepared remarks.
“We believe that this initial adoption of DarioHealth’s BGM platform by the clinical side of the industry will broaden our revenue stream beyond the device and strip business. By doing so, we will be able to make key learnings as we continue to develop new products and services to improve the greater healthcare ecosystem. Our vision for the future includes more solutions that pick up where the Dario blood glucose monitoring system ends and I believe this all begins today, as we assist a pharmaceutical company in their clinical study,” he added.
